Evidence map›Paper›PMID 40778177›Full record

ArticlemedRxiv : the preprint server for health sciences2025

The PREVENT-AD cohort: accelerating Alzheimer's disease research and treatment in Canada and beyond.

Sylvia Villeneuve, Judes Poirier, John C S Breitner, Jennifer Tremblay-Mercier, Jordana Remz, Jean-Michel Raoult, Yara Yakoub, Jonathan Gallego-Rudolf, Ting Qiu, Alfonso Fajardo Valdez and 35 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

45 authors.

Sylvia VilleneuveStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.ORCID 0000-0003-2338-0467
Judes PoirierStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
John C S BreitnerStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
Jennifer Tremblay-MercierStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
Jordana RemzStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
Jean-Michel RaoultStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
Yara YakoubStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
Jonathan Gallego-RudolfStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
Ting QiuStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
Alfonso Fajardo ValdezStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
Bery MohammediyanStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
Mohammadali JavanrayStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
Amelie MetzStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
Safa SanamiDepartment of Physics, Concordia University, Montréal, QC H4B 1R6, Canada.
Valentin OurryStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
Alfie WearnDepartment of Neurology and Neurosurgery, McGill University, Montréal, QC H3A 1A1, Canada.
Alexandre Pastor-BernierStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.ORCID 0000-0001-5218-3337
Manon EddeStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
Julie GonneaudStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
Cherie Strikwerda-BrownStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
Christine L TardifMcConnell Brain Imaging Center, Montreal Neurological Institute, McGill University, Montréal, QC H3A 2B4, Canada.
Claudine J GauthierStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
Maxime DescoteauxFaculté des sciences, Département d'informatique, Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.
Mahsa DadarStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
Étienne Vachon-PresseauStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
Andree-Ann BarilResearch Center of the CIUSSS-NIM, Hôpital du Sacré-Coeur de Montréal, Montreal, QC H4J 1C5, Canada.
Simon DucharmeStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
Maxime MontembeaultStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
Maiya R GeddesStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
Jean-Paul SoucyMcConnell Brain Imaging Center, Montreal Neurological Institute, McGill University, Montréal, QC H3A 2B4, Canada.
Natasha RajahDepartment of Psychology, Toronto Metropolitan University, Toronto, ON M5S 2E5, Canada.
Robert LaforceClinique interdisciplinaire de mémoire, CHU de Québec affilié à l'Université Laval, Québec, QC G1V 4G2, Canada.
Christian BoctiDivision of Neurology, Department of Medicine, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5H3, Canada.
Christos DavatzikosAI2D Center for AI and Data Science for Integrated Diagnostics, University of Pennsylvania, Philadelphia, PA 19104, USA.
Lune BellecPsychology Department, Université de Montréal, Montréal, QC H2V 2S9, Canada.
Pedro Rosa-NetoDepartment of Psychiatry, McGill University, Montréal, QC H3A 1A1, Canada.
Sylvain BailletMcConnell Brain Imaging Center, Montreal Neurological Institute, McGill University, Montréal, QC H3A 2B4, Canada.
Alan C EvansMcConnell Brain Imaging Center, Montreal Neurological Institute, McGill University, Montréal, QC H3A 2B4, Canada.
D Louis CollinsMcConnell Brain Imaging Center, Montreal Neurological Institute, McGill University, Montréal, QC H3A 2B4, Canada.
M Mallar ChakravartyDepartment of Psychiatry, McGill University, Montréal, QC H3A 1A1, Canada.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, 431 39 Mölndal, Sweden.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, 431 39 Mölndal, Sweden.
R Nathan SprengStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
Alexa Pichet BinetteStoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
PREVENT-AD Research Group

Funding

BrainStorm: Highly Extensible Software for Advanced Electrophysiology and MEG/EEG ImagingR01EB026299 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LEAHY, RICHARD M · 2018 to 2025
$5.4M
Core B - Pilot StudiesP30AG048785 · NIA · BRANDEIS UNIVERSITY · PI LACHMAN, MARGIE E · 2014 to 2023
$4.5M
Investigating the impact of loneliness on brain aging and pre-symptomatic Alzheimer's disease progressionR01AG068563 · NIA · MCGILL UNIVERSITY · PI BZDOK, DANILO, SPRENG, ROBERT NATHAN · 2020 to 2024
$2.3M
NIA NIH HHS P30 AG048785NIA NIH HHS R01 AG068563NIBIB NIH HHS R01 EB026299
6 · The paper itself

Abstract

The PREVENT-AD is an investigator-driven study that was created in 2011 and enrolled cognitively normal older adults with a family history of sporadic AD. Participants are deeply phenotyped and have now been followed annually for more than 12 years [median follow-up 8.0 years,SD 3.1]. Multimodal MRI, genetic, neurosensory, clinical, cerebrospinal fluid and cognitive data collected until 2017 on 348 participants who agreed to open sharing with the neuroscience community were already available. We now share a new release including 6 years of additional follow-up cognitive data, and additional MRI follow-ups, clinical progression, new longitudinal behavioral and lifestyle measures (questionnaires, actigraphy), longitudinal AD plasma biomarkers, amyloid-beta and tau PET, magnetoencephalography, as well as neuroimaging analytic measures from all MRI modalities. We describe the PREVENT-AD study, the data shared with the global research community as well as the model we created to sustain longitudinal follow-ups while also allowing new innovative data collection.

Indexed as

Biomarkersclinical progressioncognitiondata repositoryneuroimagingpreclinical

Identifiers

PMID40778177
PMCPMC12330406

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.